Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 545493, 24 pages
http://dx.doi.org/10.1155/2014/545493
Review Article

Cytokines as Biomarkers in Rheumatoid Arthritis

1Leeds Institute of Rheumatic and Musculoskeletal Medicine, The University of Leeds, Leeds, UK
2Leeds Institute of Cancer and Pathology Research, The University of Leeds, Leeds, UK
3NIHR Leeds Musculoskeletal Biomedical Research Unit, The Leeds Trust Teaching Hospital, Leeds, UK
4Leeds Institute of Rheumatic and Musculoskeletal Medicine, Translational Research in Immune Mediated Inflammatory Diseases Group, Clinical Sciences Building, St. James’s University Hospital, Leeds LS9 7TF, UK

Received 28 August 2013; Accepted 21 January 2014; Published 9 March 2014

Academic Editor: Jean Sibilia

Copyright © 2014 Agata Burska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Avouac, L. Gossec, and M. Dougados, “Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in Rheumatoid Arthritis: a systematic literature review,” Annals of the Rheumatic Diseases, vol. 65, no. 7, pp. 845–851, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Goëb, P. Aegerter, R. Parmar et al., “Progression to Rheumatoid Arthritis in early inflammatory arthritis is associated with low IL-7 serum levels,” Annals of the Rheumatic Diseases, vol. 72, no. 6, pp. 1032–1036, 2013. View at Publisher · View at Google Scholar
  3. D. M. Gerlag, K. Raza, L. G. M. van Baarsen et al., “EULAR recommendations for terminology and research in individuals at risk of Rheumatoid Arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis,” Annals of the Rheumatic Diseases, vol. 71, no. 5, pp. 638–641, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Shi, R. Knevel, P. Suwannalai et al., “Autoantibodies recognizing carbamylated proteins are present in sera of patients with Rheumatoid Arthritis and predict joint damage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 42, pp. 17372–17377, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Shi, A. Willemze, G. M. C. Janssen et al., “Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the “AMC-Senshu” method,” Annals of the Rheumatic Diseases, vol. 72, no. 1, pp. 148–150, 2013. View at Publisher · View at Google Scholar
  6. D. Aletaha, T. Neogi, A. J. Silman et al., “Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative,” Arthritis & Rheumatism, vol. 62, no. 9, pp. 2569–2581, 2010. View at Publisher · View at Google Scholar
  7. C. Burgoyne, E. Vital, S. Dass, D. Corscadden, P. Emery, and F. Ponchel, “Alteration of B cell phenotype following depletion with rituximab in Rheumatoid Arthritis,” in Proceedings of the 28th European Workshop for Rheumatology Research (EWRR '08), Toulouse, France, 2008.
  8. B. Saleem, H. Keen, and V. Goeb, “Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?” Annals of the Rheumatic Diseases, vol. 69, no. 9, pp. 1636–1642, 2010. View at Publisher · View at Google Scholar
  9. F. Ponchel, V. Goëb, R. Parmar et al., “An immunological biomarker to predict MTX response in early RA,” Annals of the Rheumatic Diseases, 2013. View at Publisher · View at Google Scholar
  10. S. Ramiro, P. Machado, J. A. Singh, R. B. Landewé, and J. A. P. da Silva, “Applying science in practice: the optimization of biological therapy in Rheumatoid Arthritis,” Arthritis Research & Therapy, vol. 12, no. 6, article 220, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Fueldner, A. Mittag, J. Knauer et al., “Identification and evaluation of novel synovial tissue biomarkers in Rheumatoid Arthritis by laser scanning cytometry,” Arthritis Research & Therapy, vol. 14, no. 1, article R8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. S. M. Churchman, J. Geiler, R. Parmar et al., “Multiplexing immunoassays for cytokine detection in the serum of patients with Rheumatoid Arthritis: lack of sensitivity and interference by rheumatoid factor,” Clinical and Experimental Rheumatology, vol. 30, no. 4, pp. 534–542, 2012. View at Google Scholar
  13. A. M. Prince, B. Brotman, D. Jass, and H. Ikram, “Specificity of the direct solid-phase radioimmunoassay for detection of hepatitis-B antigen,” The Lancet, vol. 1, no. 7816, pp. 1346–1350, 1973. View at Google Scholar · View at Scopus
  14. W. M. Hunter and P. S. Budd, “Circulating antibodies to ovine and bovine immunoglobulin in healthy subjects: a hazard for immunoassays,” The Lancet, vol. 2, no. 8204, p. 1136, 1980. View at Publisher · View at Google Scholar · View at Scopus
  15. P. J. Howanitz, J. H. Howanitz, H. V. Lamberson, and K. M. Ennis, “Incidence and mechanism of spurious increases in serum thyrotropin,” Clinical Chemistry, vol. 28, no. 3, pp. 427–431, 1982. View at Google Scholar · View at Scopus
  16. M. H. Zweig, G. Csako, C. C. Benson, B. D. Weintraub, and B. B. Kahn, “Interference by anti-immunoglobulin G antibodies in immunoradiometric assays of thyrotropin involving mouse monoclonal antibodies,” Clinical Chemistry, vol. 33, no. 6, pp. 840–844, 1987. View at Google Scholar · View at Scopus
  17. J.-F. Benoist, D. Orbach, and D. Biou, “False increase in C-reactive protein attributable to heterophilic antibodies in two renal transplant patients treated with rabbit antilymphocyte globulin,” Clinical Chemistry, vol. 44, no. 9, pp. 1980–1985, 1998. View at Google Scholar · View at Scopus
  18. L. M. Boscato and M. C. Stuart, “Heterophilic antibodies: a problem for all immunoassays,” Clinical Chemistry, vol. 34, no. 1, pp. 27–33, 1988. View at Google Scholar · View at Scopus
  19. M. H. Nahm and J. W. Hoffmann, “Heteroantibody: phantom of the immunoassay,” Clinical Chemistry, vol. 36, no. 6, p. 829, 1990. View at Google Scholar · View at Scopus
  20. T. B. Martins, “Development of internal controls for the Luminex instrument as part of a multiplex seven-analyte viral respiratory antibody profile,” Clinical and Diagnostic Laboratory Immunology, vol. 9, no. 1, pp. 41–45, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. W. de Jager, B. J. Prakken, J. W. J. Bijlsma, W. Kuis, and G. T. Rijkers, “Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies,” Journal of Immunological Methods, vol. 300, no. 1-2, pp. 124–135, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. W. de Jager and G. T. Rijkers, “Solid-phase and bead-based cytokine immunoassay: a comparison,” Methods, vol. 38, no. 4, pp. 294–303, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Hueber, B. H. Tomooka, X. Zhao et al., “Proteomic analysis of secreted proteins in early Rheumatoid Arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines,” Annals of the Rheumatic Diseases, vol. 66, no. 6, pp. 712–719, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Longmore, I. Wilkinson, E. Davidson, A. Foulkes, and A. Mafi, Oxford Handbook of Clinical Medicine, Oxford University Press, 2010.
  25. V. Agnello, A. Arbetter, and G. I. de Kasep, “Evidence for a subset of rheumatoid factors that cross-react with DNA-histone and have a distinct cross-idiotype,” Journal of Experimental Medicine, vol. 151, no. 6, pp. 1514–1527, 1980. View at Google Scholar · View at Scopus
  26. P. W. Thavasu, S. Longhurst, S. P. Joel, M. L. Slevin, and F. R. Balkwill, “Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions,” Journal of Immunological Methods, vol. 153, no. 1-2, pp. 115–124, 1992. View at Google Scholar · View at Scopus
  27. H.-L. Wong, R. M. Pfeiffer, T. R. Fears, R. Vermeulen, S. Ji, and C. S. Rabkin, “Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons,” Cancer Epidemiology Biomarkers & Prevention, vol. 17, no. 12, pp. 3450–3456, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Patil, S. Shukre, R. Paranjape, and M. Thakar, “Heparin and EDTA anticoagulants differentially affect the plasma cytokine levels in humans,” Scandinavian Journal of Clinical & Laboratory Investigation, vol. 73, no. 5, pp. 452–455, 2013. View at Publisher · View at Google Scholar
  29. R. P. Jackman, G. H. Utter, J. W. Heitman et al., “Effects of blood sample age at time of separation on measured cytokine concentrations in human plasma,” Clinical and Vaccine Immunology, vol. 18, no. 2, pp. 318–326, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Skogstrand, C. K. Ekelund, P. Thorsen et al., “Effects of blood sample handling procedures on measurable inflammatory markers in plasma, serum and dried blood spot samples,” Journal of Immunological Methods, vol. 336, no. 1, pp. 78–84, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Riches, R. Gooding, B. C. Millar, and A. W. Rowbottom, “Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNF-α concentrations,” Journal of Immunological Methods, vol. 153, no. 1-2, pp. 125–131, 1992. View at Google Scholar · View at Scopus
  32. G. Leroux-Roels, J. Philippe, F. Offner, and A. Vermeulen, “In-vitro production of cytokines in blood,” The Lancet, vol. 336, no. 8724, p. 1197, 1990. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Biancotto, X. Feng, M. Langweiler, N. S. Young, and J. P. McCoy, “Effect of anticoagulants on multiplexed measurement of /chemokines in healthy subjects,” Cytokine, vol. 60, no. 2, pp. 438–446, 2012. View at Publisher · View at Google Scholar
  34. L. Flower, R. H. Ahuja, S. E. Humphries, and V. Mohamed-Ali, “Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-α and leptin,” Cytokine, vol. 12, no. 11, pp. 1712–1716, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. R. de Jongh, J. Vranken, G. Vundelinckx, E. Bosmans, M. Maes, and R. Heylen, “The effects of anticoagulation and processing on assays of IL-6, sIL-6R, sIL-2R and soluble transferrin receptor,” Cytokine, vol. 9, no. 9, pp. 696–701, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. J. B. Eggesbø, I. Hjermann, A. T. Høstmark, and P. Kierulf, “LPS induced release of IL-1β, IL-6, IL-8 and TNF-α in EDTA or heparin anticoagulated whole blood from persons with high or low levels of serum HDL,” Cytokine, vol. 8, no. 2, pp. 152–160, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Kenis, C. Teunissen, R. de Jongh, E. Bosmans, H. Steinbusch, and M. Maes, “Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum,” Cytokine, vol. 19, no. 5, pp. 228–235, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. S. W. Read, A. Rupert, R. Stevens, A. O'Shea, and I. Sereti, “Delayed sample processing leads to marked decreases in measured plasma IL-7 levels,” Journal of Acquired Immune Deficiency Syndromes, vol. 42, no. 4, pp. 511–512, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Aziz, P. Nishanian, R. Mitsuyasu, R. Detels, and J. L. Fahey, “Variables that affect assays for plasma cytokines and soluble activation markers,” Clinical and Diagnostic Laboratory Immunology, vol. 6, no. 1, pp. 89–95, 1999. View at Google Scholar · View at Scopus
  40. J. Lengellé, E. Panopoulos, and F. Betsou, “Soluble CD40 ligand as a biomarker for storage-related preanalytic variations of human serum,” Cytokine, vol. 44, no. 2, pp. 275–282, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Redl, S. Bahrami, G. Leichtfried, and G. Schlag, “Special collection and storage tubes for blood endotoxin and cytokine measurements,” Clinical Chemistry, vol. 38, no. 5, pp. 764–765, 1992. View at Google Scholar · View at Scopus
  42. A. R. Exley and J. Cohen, “Optimal collection of blood samples for the measurement of tumor necrosis factor α,” Cytokine, vol. 2, no. 5, pp. 353–356, 1990. View at Google Scholar · View at Scopus
  43. G. Leroux-Roels, F. Offner, J. Philippe, and A. Vermeulen, “Influence of blood-collecting systems on concentrations of tumor necrosis factor in serum and plasma,” Clinical Chemistry, vol. 34, no. 11, pp. 2373–2374, 1988. View at Google Scholar · View at Scopus
  44. R. Zimmermann, J. Koenig, J. Zingsem et al., “Effect of specimen anticoagulation on the measurement of circulating platelet-derived growth factors,” Clinical Chemistry, vol. 51, no. 12, pp. 2365–2368, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. D. J. Grainger, D. E. Mosedale, and J. C. Metcalfe, “TGF-β in blood: a complex problem,” Cytokine & Growth Factor Reviews, vol. 11, no. 1-2, pp. 133–145, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Kropf, J. O. Schurek, A. Wollner, and A. M. Gressner, “Immunological measurement of transforming growth factor-beta I (TGF- β1) in blood; assay development and comparison,” Clinical Chemistry, vol. 43, no. 10, pp. 1965–1974, 1997. View at Google Scholar · View at Scopus
  47. L. M. Wakefield, J. J. Letterio, T. Chen et al., “Transforming growth factor-β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer,” Clinical Cancer Research, vol. 1, no. 1, pp. 129–136, 1995. View at Google Scholar · View at Scopus
  48. C. Chaigneau, T. Cabioch, K. Beaumont, and F. Betsou, “Serum biobank certification and the establishment of quality controls for biological fluids: examples of serum biomarker stability after temperature variation,” Clinical Chemistry and Laboratory Medicine, vol. 45, no. 10, pp. 1390–1395, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Zhao, L. Wang, W. Ji, M. Lei, W. Yang, and F.-M. Kong, “The influence of the blood handling process on the measurement of circulating TGF-β1,” European Cytokine Network, vol. 23, no. 1, pp. 1–6, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. A. M. Halldórsdóttir, J. Stoker, R. Porche-Sorbet, and C. S. Eby, “Soluble CD40 ligand measurement inaccuracies attributable to specimen type, processing time, and ELISA method,” Clinical Chemistry, vol. 51, no. 6, pp. 1054–1057, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Bereczki, E. Nagy, A. Pál et al., “Should soluble CD40 ligand be measured from serum or plasma samples?” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 6, pp. 1129–1131, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Varo, R. Nuzzo, C. Natal, P. Libby, and U. Schönbeck, “Influence of pre-analytical and analytical factors on soluble CD40L measurements,” Clinical Science, vol. 111, no. 5, pp. 341–347, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. D. Malone, L. M. Napolitano, T. Genuit, G. V. Bochicchio, K. Kole, and T. M. Scalea, “Total cytokine immunoassay: a more accurate method of cytokine measurement?” The Journal of Trauma, vol. 50, no. 5, pp. 821–825, 2001. View at Google Scholar · View at Scopus
  54. R. E. Banks, “Measurement of cytokines in clinical samples using immunoassays: problems and pitfalls,” Critical Reviews in Clinical Laboratory Sciences, vol. 37, no. 2, pp. 131–182, 2000. View at Google Scholar · View at Scopus
  55. M. Wadhwa and R. Thorpe, “Cytokine immunoassays: recommendations for standardisation, calibration and validation,” Journal of Immunological Methods, vol. 219, no. 1-2, pp. 1–5, 1998. View at Publisher · View at Google Scholar · View at Scopus
  56. G. V. Shurin, Z. R. Yurkovetsky, G. S. Chatta, I. L. Tourkova, M. R. Shurin, and A. E. Lokshin, “Dynamic alteration of soluble serum biomarkers in healthy aging,” Cytokine, vol. 39, no. 2, pp. 123–129, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Bruunsgaard and B. K. Pedersen, “Age-related inflammatory cytokines and disease,” Immunology and Allergy Clinics of North America, vol. 23, no. 1, pp. 15–39, 2003. View at Google Scholar
  58. H. Bruunsgaard, M. Pedersen, and B. K. Pedersen, “Aging and proinflammatory cytokines,” Current Opinion in Hematology, vol. 8, no. 3, pp. 131–136, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. R. J. Forsey, J. M. Thompson, J. Ernerudh et al., “Plasma cytokine profiles in elderly humans,” Mechanisms of Ageing and Development, vol. 124, no. 4, pp. 487–493, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. K. S. Krabbe, M. Pedersen, and H. Bruunsgaard, “Inflammatory mediators in the elderly,” Experimental Gerontology, vol. 39, no. 5, pp. 687–699, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. T. Fulop, A. Larbi, N. Douziech, I. Levesque, A. Varin, and G. Herbein, “Cytokine receptor signalling and aging,” Mechanisms of Ageing and Development, vol. 127, no. 6, pp. 526–537, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Gerli, D. Monti, O. Bistoni et al., “Chemokines, sTNF-Rs and sCD30 serum levels in healthy aged people and centenarians,” Mechanisms of Ageing and Development, vol. 121, no. 1–3, pp. 37–46, 2001. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Myśliwska, E. Bryl, J. Foerster, and A. Myśliwski, “The upregulation of TNFα production is not a generalised phenomenon in the elderly between their sixth and seventh decades of life,” Mechanisms of Ageing and Development, vol. 107, no. 1, pp. 1–14, 1999. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Bruunsgaard, K. Andersen-Ranberg, J. V. B. Hjelmborg, B. K. Pedersen, and B. Jeune, “Elevated levels of tumor necrosis factor alpha and mortality in centenarians,” American Journal of Medicine, vol. 115, no. 4, pp. 278–283, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. F. Licastro, G. Candore, D. Lio et al., “Innate immunity and inflammation in ageing: a key for understanding age-related diseases,” Immunity and Ageing, vol. 2, article 8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Vasto, G. Candore, C. R. Balistreri et al., “Inflammatory networks in ageing, age-related diseases and longevity,” Mechanisms of Ageing and Development, vol. 128, no. 1, pp. 83–91, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. G. Pawelec, A. Larbi, and E. Derhovanessian, “Senescence of the human immune system,” Journal of Comparative Pathology, vol. 142, no. 1, pp. S39–S44, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. C. C. Finnerty, M. G. Jeschke, D. N. Herndon et al., “Temporal cytokine profiles in severely burned patients: a comparison of adults and children,” Molecular Medicine, vol. 14, no. 9-10, pp. 553–560, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. S. A. Ahmed, B. D. Hissong, D. Verthelyi, K. Donner, K. Becker, and E. Karpuzoglu-Sahin, “Gender and risk of autoimmune diseases: possible role of estrogenic compounds,” Environmental Health Perspectives, vol. 107, supplement 5, pp. 681–686, 1999. View at Google Scholar · View at Scopus
  70. A. B. Hahn, J. C. Kasten-Jolly, D. M. Constantino et al., “TNF-α, IL-6, IFN-γ, and IL-10 gene expression polymorphisms and the IL-4 receptor α-chain variant Q576R: effects on renal allograft outcome,” Transplantation, vol. 72, no. 4, pp. 660–665, 2001. View at Google Scholar · View at Scopus
  71. M. J. Eikelenboom, J. Killestein, J. J. Kragt, B. M. J. Uitdehaag, and C. H. Polman, “Gender differences in multiple sclerosis: cytokines and vitamin D,” Journal of the Neurological Sciences, vol. 286, no. 1-2, pp. 40–42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Sadeghi, V. Daniel, C. Naujokat, M. Wiesel, O. Hergesell, and G. Opelz, “Strong inflammatory cytokine response in male and strong anti-inflammatory response in female kidney transplant recipients with urinary tract infection,” Transplant International, vol. 18, no. 2, pp. 177–185, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. P. Pietschmann, E. Gollob, S. Brosch et al., “The effect of age and gender on cytokine production by human peripheral blood mononuclear cells and markers of bone metabolism,” Experimental Gerontology, vol. 38, no. 10, pp. 1119–1127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. N. Petrovsky, P. McNair, and L. C. Harrison, “Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications,” Cytokine, vol. 10, no. 4, pp. 307–312, 1998. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Cutolo, B. Seriolo, C. Craviotto, C. Pizzorni, and A. Sulli, “Circadian rhythms in RA,” Annals of the Rheumatic Diseases, vol. 62, no. 7, pp. 593–596, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Cutolo and R. H. Straub, “Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction,” Autoimmunity Reviews, vol. 7, no. 3, pp. 223–228, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. P. Lissoni, F. Rovelli, F. Brivio, O. Brivio, and L. Fumagalli, “Circadian secretions of IL-2, IL-12, IL-6 and IL-10 in relation to the light/dark rhythm of the pineal hormone melatonin in healthy humans,” Natural Immunity, vol. 16, no. 1, pp. 1–5, 1998. View at Publisher · View at Google Scholar · View at Scopus
  78. L. S. Knudsen, I. J. Christensen, T. Lottenburger et al., “Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with Rheumatoid Arthritis,” Biomarkers, vol. 13, no. 1, pp. 59–78, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. N. G. Arvidson, B. Gudbjornsson, L. Elfman, A.-C. Ryden, T. H. Totterman, and R. Hallgren, “Circadian rhythm of serum interleukin-6 in Rheumatoid Arthritis,” Annals of the Rheumatic Diseases, vol. 53, no. 8, pp. 521–524, 1994. View at Google Scholar · View at Scopus
  80. R. H. Straub and M. Cutolo, “Circadian rhythms in Rheumatoid Arthritis: implications for pathophysiology and therapeutic management,” Arthritis & Rheumatism, vol. 56, no. 2, pp. 399–408, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Cutolo, B. Villaggio, K. Otsa, O. Aakre, A. Sulli, and B. Seriolo, “Altered circadian rhythms in Rheumatoid Arthritis patients play a role in the disease's symptoms,” Autoimmunity Reviews, vol. 4, no. 8, pp. 497–502, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. L. J. Crofford, K. T. Kalogeras, G. Mastorakos et al., “Circadian relationships between interleukin (IL)-6 and hypothalamic- pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated Rheumatoid Arthritis,” Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 4, pp. 1279–1283, 1997. View at Publisher · View at Google Scholar · View at Scopus
  83. P. Dandona, R. Weinstock, K. Thusu, E. Abdel-Rahman, A. Aljada, and T. Wadden, “Tumor necrosis factor-α in sera of obese patients: fall with weight loss,” Journal of Clinical Endocrinology & Metabolism, vol. 83, no. 8, pp. 2907–2910, 1998. View at Publisher · View at Google Scholar · View at Scopus
  84. P. Blackburn, J.-P. Després, B. Lamarche et al., “Postprandial variations of plasma inflammatory markers in abdominally obese men,” Obesity, vol. 14, no. 10, pp. 1747–1754, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. C. Payette, P. Blackburn, B. Lamarche et al., “Sex differences in postprandial plasma tumor necrosis factor-α, interleukin-6, and C-reactive protein concentrations,” Metabolism, vol. 58, no. 11, pp. 1593–1601, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. A. J. Saah and D. R. Hoover, “‘Sensitivity” and “specificity” reconsidered: the meaning of these terms in analytical and diagnostic settings,” Annals of Internal Medicine, vol. 126, no. 1, pp. 91–94, 1997. View at Google Scholar · View at Scopus
  87. N. W. Tietz, C. A. Burtis, and E. R. Ashwood, Tietz Textbook of Clinical Chemistry, WB Saunders, 1994.
  88. K. Esposito, F. Nappo, R. Marfella et al., “Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress,” Circulation, vol. 106, no. 16, pp. 2067–2072, 2002. View at Publisher · View at Google Scholar · View at Scopus
  89. M. F. Carroll and D. S. Schade, “Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers,” Circulation, vol. 108, no. 1, pp. 24–31, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. X. Zhou, M. S. Fragala, J. E. McElhaney, and G. A. Kuchel, “Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 13, no. 5, pp. 541–547, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. R. F. Grimble, “Nutritional modulation of cytokine biology,” Nutrition, vol. 14, no. 7-8, pp. 634–640, 1998. View at Publisher · View at Google Scholar · View at Scopus
  92. D. G. Rowbottom and K. J. Green, “Acute exercise effects on the immune system,” Medicine and Science in Sports & Exercise, vol. 32, no. 7, pp. S396–S405, 2000. View at Google Scholar · View at Scopus
  93. K. Ostrowski, T. Rohde, M. Zacho, S. Asp, and B. K. Pedersen, “Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running,” Journal of Physiology, vol. 508, no. 3, pp. 949–953, 1998. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Steensberg, C. Keller, R. L. Starkie, T. Osada, M. A. Febbraio, and B. K. Pedersen, “IL-6 and TNF-α expression in, and release from, contracting human skeletal muscle,” American Journal of Physiology, vol. 283, no. 6, pp. E1272–E1278, 2002. View at Google Scholar · View at Scopus
  95. H. Gabriel and W. Kindermann, “The acute immune response to exercise: what does it mean?” International Journal of Sports Medicine, vol. 18, no. 1, pp. S28–S45, 1997. View at Google Scholar · View at Scopus
  96. D. C. Nieman and B. K. Pedersen, “Exercise and immune function. Recent developments,” Sports Medicine, vol. 27, no. 2, pp. 73–80, 1999. View at Publisher · View at Google Scholar · View at Scopus
  97. B. K. Pedersen, A. Steensberg, C. Fischer et al., “The metabolic role of IL-6 produced during exercise: is IL-6 an exercise factor?” Proceedings of the Nutrition Society, vol. 63, no. 2, pp. 263–267, 2004. View at Publisher · View at Google Scholar · View at Scopus
  98. M. A. Febbraio and B. K. Pedersen, “Muscle-derived interleukin-6: mechanisms for activation and possible biological roles,” The FASEB Journal, vol. 16, no. 11, pp. 1335–1347, 2002. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Penkowa, C. Keller, P. Keller, S. Jauffred, and B. K. Pedersen, “Immunohistochemical detection of interleukin-6 in human skeletal muscle fibers following exercise,” The FASEB Journal, vol. 17, no. 14, pp. 2166–2168, 2003. View at Google Scholar · View at Scopus
  100. B. Baslund, K. Lyngberg, V. Andersen et al., “Effect of 8 wk of bicycle training on the immune system of patients with Rheumatoid Arthritis,” Journal of Applied Physiology, vol. 75, no. 4, pp. 1691–1695, 1993. View at Google Scholar · View at Scopus
  101. N. P. Walsh, M. Gleeson, R. J. Shephard et al., “Position statement. Part one: immune function and exercise,” Exercise Immunology Review, vol. 17, no. 1, pp. 6–63, 2011. View at Google Scholar
  102. A. N. Vgontzas, E. Zoumakis, E. O. Bixler et al., “Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines,” Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 5, pp. 2119–2126, 2004. View at Publisher · View at Google Scholar · View at Scopus
  103. R. A. Barratt, S. L. Bowens, S. K. McCune, J. N. Johannessen, and S. Y. Buckman, “The critical path initiative: leveraging collaborations to enhance regulatory science,” Clinical Pharmacology and Therapeutics, vol. 91, no. 3, pp. 380–383, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Lekander, S. Elofsson, I.-M. Neve, L.-O. Hansson, and A.-L. Unden, “Self-rated health is related to levels of circulating cytokines,” Psychosomatic Medicine, vol. 66, no. 4, pp. 559–563, 2004. View at Publisher · View at Google Scholar · View at Scopus
  105. D. de Groote, P. F. Zangerle, Y. Gevaert et al., “Direct stimulation of cytokines (IL-1β, TNF-α, IL-6, IL-2, IFN-γ and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation,” Cytokine, vol. 4, no. 3, pp. 239–248, 1992. View at Google Scholar · View at Scopus
  106. T. C. Peakman and P. Elliott, “The UK Biobank sample handling and storage validation studies,” International Journal of Epidemiology, vol. 37, supplement 1, pp. i2–i6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. J. A. D. Bienvenu, G. Monneret, M. C. Gutowski, and N. Fabien, “Cytokine assays in human sera and tissues,” Toxicology, vol. 129, no. 1, pp. 55–61, 1998. View at Publisher · View at Google Scholar · View at Scopus
  108. S. Barelli, D. Crettaz, L. Thadikkaran, O. Rubin, and J.-D. Tissot, “Plasma/serum proteomics: pre-analytical issues,” Expert Review of Proteomics, vol. 4, no. 3, pp. 363–370, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. F. S. Hosnijeh, E. J. M. Krop, L. Portengen et al., “Stability and reproducibility of simultaneously detected plasma and serum cytokine levels in asymptomatic subjects,” Biomarkers, vol. 15, no. 2, pp. 140–148, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. J. G. Cannon, J. W. M. van der Meer, D. Kwiatkowski et al., “Interleukin-1β in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods,” Lymphokine Research, vol. 7, no. 4, pp. 457–467, 1988. View at Google Scholar · View at Scopus
  111. T. L. Whiteside, “Cytokines and cytokine measurements in a clinical laboratory,” Clinical and Diagnostic Laboratory Immunology, vol. 1, no. 3, pp. 257–260, 1994. View at Google Scholar · View at Scopus
  112. J. N. Hoffmann, W. H. Hartl, E. Faist, M. Jochum, and D. Inthorn, “Tumor necrosis factor measurement and use of different anticoagulants: possible interference in plasma samples and supernatants from endotoxin-stimulated monocytes,” Inflammation Research, vol. 46, no. 9, pp. 342–347, 1997. View at Publisher · View at Google Scholar · View at Scopus
  113. N. Aziz, M. R. Irwin, S. S. Dickerson, and A. W. Butch, “Spurious tumor necrosis factor-α and interleukin-6 production by human monocytes from blood collected in endotoxin-contaminated vacutainer blood collection tubes,” Clinical Chemistry, vol. 50, no. 11, pp. 2215–2216, 2004. View at Publisher · View at Google Scholar · View at Scopus
  114. J. J. Deeks, “Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests,” British Medical Journal, vol. 323, no. 7305, pp. 157–162, 2001. View at Google Scholar · View at Scopus
  115. S. Gilbertson-White, B. E. Aouizerat, and C. Miaskowski, “Methodologic issues in the measurement of cytokines to elucidate the biological basis for cancer symptoms,” Biological Research for Nursing, vol. 13, no. 1, pp. 15–24, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. S. S. Tworoger and S. E. Hankinson, “Collection, processing, and storage of biological samples in epidemiologic studies: sex hormones, carotenoids, inflammatory markers, and proteomics as examples,” Cancer Epidemiology Biomarkers & Prevention, vol. 15, no. 9, pp. 1578–1581, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. A. Czlonkowska, A. Ciesielska, G. Gromadzka, and I. Kurkowska-Jastrzebska, “Estrogen and cytokines production—the possible cause of gender differences in neurological diseases,” Current Pharmaceutical Design, vol. 11, no. 8, pp. 1017–1030, 2005. View at Publisher · View at Google Scholar · View at Scopus
  118. B. B. Haab, B. H. Geierstanger, G. Michailidis et al., “Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data,” Proteomics, vol. 5, no. 13, pp. 3278–3291, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. R. A. R. Bowen, Y. Chan, J. Cohen et al., “Effect of blood collection tubes on total triiodothyronine and other laboratory assays,” Clinical Chemistry, vol. 51, no. 2, pp. 424–433, 2005. View at Publisher · View at Google Scholar · View at Scopus
  120. X. Zhao, F. Qureshi, P. S. Eastman et al., “Pre-analytical effects of blood sampling and handling in quantitative immunoassays for Rheumatoid Arthritis,” Journal of Immunological Methods, vol. 378, no. 1-2, pp. 72–80, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. G. Panicker, K. S. Meadows, D. R. Lee, R. Nisenbaum, and E. R. Unger, “Effect of storage temperatures on the stability of cytokines in cervical mucous,” Cytokine, vol. 37, no. 2, pp. 176–179, 2007. View at Publisher · View at Google Scholar · View at Scopus
  122. W. de Jager, K. Bourcier, G. T. Rijkers, B. J. Prakken, and V. Seyfert-Margolis, “Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays,” BMC Immunology, vol. 10, article 52, 2009. View at Publisher · View at Google Scholar · View at Scopus
  123. M. W. van der Linden, T. W. J. Huizinga, D.-J. Stoeken, A. Sturk, and R. G. J. Westendorp, “Determination of tumour necrosis factor-α and interleukin-10 production in a whole blood stimulation system: assessment of laboratory error and individual variation,” Journal of Immunological Methods, vol. 218, no. 1-2, pp. 63–71, 1998. View at Publisher · View at Google Scholar · View at Scopus
  124. C. A. Ray, C. Dumaual, M. Willey et al., “Optimization of analytical and pre-analytical variables associated with an ex vivo cytokine secretion assay,” Journal of Pharmaceutical and Biomedical Analysis, vol. 41, no. 1, pp. 189–195, 2006. View at Publisher · View at Google Scholar · View at Scopus
  125. G. Leroux-Roels, F. Offner, J. Philippe, and A. Vermeulen, “Influence of blood-collecting systems on concentrations of tumor necrosis factor in serum and plasma,” Clinical Chemistry, vol. 34, no. 11, pp. 2373–2374, 1988. View at Google Scholar · View at Scopus
  126. R. Thorpe, M. Wadhwa, C. R. Bird, and A. R. Mire-Sluis, “Detection and measurement of cytokines,” Blood Reviews, vol. 6, no. 3, pp. 133–148, 1992. View at Publisher · View at Google Scholar · View at Scopus
  127. F.-C. Lin, R. Cohen, R. Losada, and V. Bush, “Cellular sedimentation and barrier formation under centrifugal force in blood collection tubes,” Laboratory Medicine, vol. 32, no. 10, pp. 588–594, 2001. View at Publisher · View at Google Scholar · View at Scopus
  128. N. Aziz, P. Nishanian, J. M. G. Taylor et al., “Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection,” Journal of Infectious Diseases, vol. 179, no. 4, pp. 843–848, 1999. View at Publisher · View at Google Scholar · View at Scopus
  129. A. J. Rai and F. Vitzthum, “Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics,” Expert Review of Proteomics, vol. 3, no. 4, pp. 409–426, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. A. R. Mire-Sluis, A. Padilla, and R. G. Das, “Biological standardization of cytokines and growth factors,” Developments in Biological Standardization, vol. 97, pp. 171–176, 1999. View at Google Scholar · View at Scopus
  131. N. Sachdeva and D. Asthana, “Cytokine quantitation: technologies and applications,” Frontiers in Bioscience, vol. 12, no. 12, pp. 4682–4695, 2007. View at Publisher · View at Google Scholar · View at Scopus
  132. P. Aukrust, F. Müller, E. Lien et al., “Tumor Necrosis Factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure,” Journal of Infectious Diseases, vol. 179, no. 1, pp. 74–82, 1999. View at Publisher · View at Google Scholar · View at Scopus
  133. P. Aukrust, S. S. Frøland, N.-B. Liabakk et al., “Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo,” Blood, vol. 84, no. 7, pp. 2136–2143, 1994. View at Google Scholar · View at Scopus
  134. I. Engelberts, S. Stephens, G. J. M. Francot, C. J. van der Linden, and W. A. Buurman, “Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids,” The Lancet, vol. 338, no. 8765, pp. 515–516, 1991. View at Google Scholar · View at Scopus
  135. G. Toedter, K. Hayden, C. Wagner, and C. Brodmerkel, “Simultaneous detection of eight analytes in human serum by two commercially available platforms for multiplex cytokine analysis,” Clinical and Vaccine Immunology, vol. 15, no. 1, pp. 42–48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  136. C. H. Chau, O. Rixe, H. McLeod, and W. D. Figg, “Validation of analytic methods for biomarkers used in drug development,” Clinical Cancer Research, vol. 14, no. 19, pp. 5967–5976, 2008. View at Publisher · View at Google Scholar · View at Scopus
  137. E. Morgan, R. Varro, H. Sepulveda et al., “Cytometric bead array: a multiplexed assay platform with applications in various areas of biology,” Clinical Immunology, vol. 110, no. 3, pp. 252–266, 2004. View at Publisher · View at Google Scholar · View at Scopus
  138. D. Dabitao, J. B. Margolick, J. Lopez, and J. H. Bream, “Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the Cytometric Bead Array,” Journal of Immunological Methods, vol. 372, no. 1-2, pp. 71–77, 2011. View at Publisher · View at Google Scholar · View at Scopus
  139. P. Roux-Lombard, G. Steiner, J.-M. Dayer et al., “Preliminary report on cytokine determination in human synovial fluids: a consensus study of the European Workshop for Rheumatology Research,” Clinical and Experimental Rheumatology, vol. 10, no. 5, pp. 515–520, 1992. View at Google Scholar · View at Scopus
  140. J. Bienvenu, G. Monneret, N. Fabien, and J. P. Revillard, “The clinical usefulness of the measurement of cytokines,” Clinical Chemistry and Laboratory Medicine, vol. 38, no. 4, pp. 267–285, 2000. View at Google Scholar · View at Scopus
  141. N. Madry, B. Auerbach, and C. Schelp, “Measures to overcome HAMA interferences in immunoassays,” Anticancer Research, vol. 17, no. 4, pp. 2883–2886, 1997. View at Google Scholar · View at Scopus
  142. G. Dimeski, “Interference testing,” The Clinical Biochemist Reviews, vol. 29, supplement 1, pp. S43–S48, 2008. View at Google Scholar
  143. M. Wadhwa, M. J. Seghatchian, P. Dilger et al., “Cytokines in WBC-reduced apheresis pcs during storage: a comparison of two WBC-reduction methods,” Transfusion, vol. 40, no. 9, pp. 1118–1126, 2000. View at Publisher · View at Google Scholar · View at Scopus
  144. M. Svenson, M. B. Hansen, L. Kayser, Å. K. Rasmussen, C. M. Reimert, and K. Bendtzen, “Effects of human anti-IL-1α autoantibodies on receptor binding and biological activities of IL-1,” Cytokine, vol. 4, no. 2, pp. 125–133, 1992. View at Google Scholar · View at Scopus
  145. M. B. Hansen, M. Svenson, K. Abell et al., “Sex- and age-dependency of IgG auto-antibodies against IL-1α in healthy humans,” European Journal of Clinical Investigation, vol. 24, no. 3, pp. 212–218, 1994. View at Google Scholar · View at Scopus
  146. K. Bendtzen, M. B. Hansen, M. Diamant, C. Ross, and M. Svenson, “Naturally occurring autoantibodies to interleukin-1α, interleukin-6, interleukin-10, and interferon-α,” Journal of Interferon Research, vol. 14, no. 4, pp. 157–158, 1994. View at Google Scholar · View at Scopus
  147. R. P. Revoltella, “Natural and therapeutically-induced antibodies to cytokines,” Biotherapy, vol. 10, no. 4, pp. 321–331, 1998. View at Google Scholar · View at Scopus
  148. M. B. Hansen, V. Andersen, K. Rohde et al., “Cytokine autoantibodies in Rheumatoid Arthritis,” Scandinavian Journal of Rheumatology, vol. 24, no. 4, pp. 197–203, 1995. View at Google Scholar · View at Scopus
  149. K. Chapman, “The ProteinChip Biomarker System from Ciphergen Biosystems: a novel proteomics platform for rapid biomarker discovery and validation,” Biochemical Society Transactions, vol. 30, no. 2, pp. 82–87, 2002. View at Google Scholar · View at Scopus
  150. C. M. Preissner, L. A. Dodge, D. J. O'Kane, R. J. Singh, and S. K. G. Grebe, “Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays,” Clinical Chemistry, vol. 51, no. 1, pp. 208–210, 2005. View at Publisher · View at Google Scholar · View at Scopus
  151. A. Bonetti, C. Monica, C. Bonaguri et al., “Interference by heterophilic antibodies in immunoassays: wrong increase of myoglobin values,” Acta Biomedica de l'Ateneo Parmense, vol. 79, no. 2, pp. 140–143, 2008. View at Google Scholar · View at Scopus
  152. S. S. Levinson and J. J. Miller, “Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays,” Clinica Chimica Acta, vol. 325, no. 1-2, pp. 1–15, 2002. View at Publisher · View at Google Scholar · View at Scopus
  153. N. Bolstad, D. J. Warren, J. Bjerner et al., “Heterophilic antibody interference in commercial immunoassays; a screening study using paired native and pre-blocked sera,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 12, pp. 2001–2006, 2012. View at Publisher · View at Google Scholar
  154. W. Muller, R. Mierau, and D. Wohltmann, “Interference of IgM rheumatoid factor with nephelometric C-reactive protein determinations,” Journal of Immunological Methods, vol. 80, no. 1, pp. 77–90, 1985. View at Publisher · View at Google Scholar · View at Scopus
  155. K. Raza, F. Falciani, S. J. Curnow et al., “Early Rheumatoid Arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin,” Arthritis Research & Therapy, vol. 7, no. 4, pp. R784–R795, 2005. View at Google Scholar · View at Scopus
  156. H. C. Vaidya and B. G. Beatty, “Eliminating interference from heterophilic antibodies in a two-site immunoassay for creatine kinase MB by using F(ab′)2 conjugate and polyclonal mouse IgG,” Clinical Chemistry, vol. 38, no. 9, pp. 1737–1742, 1992. View at Google Scholar · View at Scopus
  157. D. J. Todd, N. Knowlton, M. Amato et al., “Erroneous augmentation of multiplex assay measurements in patients with Rheumatoid Arthritis due to heterophilic binding by serum rheumatoid factor,” Arthritis & Rheumatism, vol. 63, no. 4, pp. 894–903, 2011. View at Publisher · View at Google Scholar · View at Scopus
  158. P. E. Chandra, J. Sokolove, B. G. Hipp et al., “Novel multiplex technology for diagnostic characterization of Rheumatoid Arthritis,” Arthritis Research & Therapy, vol. 13, no. 3, article R102, 2011. View at Publisher · View at Google Scholar · View at Scopus
  159. A. Ledur, C. Fitting, B. David, C. Hamberger, and J.-M. Cavaillon, “Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards,” Journal of Immunological Methods, vol. 186, no. 2, pp. 171–179, 1995. View at Publisher · View at Google Scholar · View at Scopus
  160. A. R. Mire-Sluis, R. G. Das, and R. Thorpe, “The international standard for Granulocyte Colony Stimulating Factor (G-CSF). Evaluation in an international collaborative study,” Journal of Immunological Methods, vol. 179, no. 1, pp. 117–126, 1995. View at Publisher · View at Google Scholar · View at Scopus
  161. A. R. Mire-Sluis, R. G. Das, and R. Thorpe, “The international standard for Macrophage Colony Stimulating Factor (M-CSF). Evaluation in an international collaborative study,” Journal of Immunological Methods, vol. 179, no. 2, pp. 141–151, 1995. View at Publisher · View at Google Scholar · View at Scopus
  162. R. E. G. Das and S. Poole, “The international standard for interleukin-6. Evaluation in an international collaborative study,” Journal of Immunological Methods, vol. 160, no. 2, pp. 147–153, 1993. View at Publisher · View at Google Scholar · View at Scopus
  163. A. R. Mire-Sluis, R. G. Das, and R. Thorpe, “Implications for the assay and biological activity of interleukin-4: results of a WHO international collaborative study,” Journal of Immunological Methods, vol. 194, no. 1, pp. 13–25, 1996. View at Publisher · View at Google Scholar
  164. A. R. Mire-Sluis, R. G. Das, and R. Thorpe, “Implications for the assay and biological activity of interleukin-8: results of a WHO international collaborative study,” Journal of Immunological Methods, vol. 200, no. 1-2, pp. 1–16, 1997. View at Publisher · View at Google Scholar · View at Scopus
  165. A. R. Mire-Sluis, R. Gaines-Das, and R. Thorpe, “Immunoassays for detecting cytokines: what are they really measuring?” Journal of Immunological Methods, vol. 186, no. 2, pp. 157–160, 1995. View at Publisher · View at Google Scholar · View at Scopus
  166. S. Poole and R. E. G. Das, “The international standards for interleukin-1α and interleukin-1β. Evaluation in an international collaborative study,” Journal of Immunological Methods, vol. 142, no. 1, pp. 1–13, 1991. View at Publisher · View at Google Scholar · View at Scopus
  167. S. Romagnani, G. del Prete, R. Manetti et al., “Role of TH1/TH2 cytokines in HIV infection,” Immunological Reviews, no. 140, pp. 73–92, 1994. View at Google Scholar · View at Scopus
  168. N. Aziz, P. Nishanian, and J. L. Fahey, “Levels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: quality control procedures,” Clinical and Diagnostic Laboratory Immunology, vol. 5, no. 6, pp. 755–761, 1998. View at Google Scholar · View at Scopus
  169. A. Meager, “Measurement of cytokines by bioassays: theory and application,” Methods, vol. 38, no. 4, pp. 237–252, 2006. View at Publisher · View at Google Scholar · View at Scopus
  170. R. V. House, “Cytokine measurement techniques for assessing hypersensitivity,” Toxicology, vol. 158, no. 1-2, pp. 51–58, 2001. View at Publisher · View at Google Scholar · View at Scopus
  171. K. J. Miller, R. R. Bowsher, A. Celniker et al., “Workshop on bioanalytical methods validation for macromolecules: summary report,” Pharmaceutical Research, vol. 18, no. 9, pp. 1373–1383, 2001. View at Publisher · View at Google Scholar · View at Scopus
  172. J. W. Lee, “Method validation and application of protein biomarkers: basic similarities and differences from biotherapeutics,” Bioanalysis, vol. 1, no. 8, pp. 1461–1474, 2009. View at Google Scholar · View at Scopus
  173. J. Smolec, B. DeSilva, W. Smith et al., “Bioanalytical method validation for macromolecules in support of pharmacokinetic studies,” Pharmaceutical Research, vol. 22, no. 9, pp. 1425–1431, 2005. View at Publisher · View at Google Scholar · View at Scopus
  174. M. L. Hetland, I. J. Christensen, T. Lottenburger et al., “Circulating VEGF as a biological marker in patients with Rheumatoid Arthritis? Preanalytical and biological variability in healthy persons and in patients,” Disease Markers, vol. 24, no. 1, pp. 1–10, 2008. View at Google Scholar · View at Scopus
  175. M. Chabaud, F. Fossiez, J.-L. Taupin, and P. Miossec, “Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by Rheumatoid Arthritis synoviocytes and its regulation by Th2 cytokines,” Journal of Immunology, vol. 161, no. 1, pp. 409–414, 1998. View at Google Scholar · View at Scopus
  176. P. Miossec, “Anti-inflammatory properties of interleukin-4,” Revue du Rhumatisme, vol. 60, no. 2, pp. 87–91, 1993. View at Google Scholar · View at Scopus
  177. F. Ponchel, R. J. Verburg, S. J. Bingham et al., “IL-7 deficiency and therapy-induced lymphopenia in Rheumatoid Arthritis,” Arthritis Research & Therapy, vol. 7, no. 1, pp. R82–R92, 2005. View at Publisher · View at Google Scholar
  178. S. M. Churchman and F. Ponchel, “Interleukin-7 in Rheumatoid Arthritis,” Rheumatology, vol. 47, no. 6, pp. 753–759, 2008. View at Publisher · View at Google Scholar · View at Scopus
  179. V. Goëb, P. Aegerter, R. Parmar et al., “Progression to Rheumatoid Arthritis in early inflammatory arthritis is associated with low IL-7 serum levels,” Annals of the Rheumatic Diseases, vol. 72, no. 6, pp. 1032–1036, 2013. View at Publisher · View at Google Scholar
  180. S. Faucher, A. M. Crawley, W. Decker et al., “Development of a quantitative bead capture assay for soluble IL-7 receptor alpha in human plasma,” PLoS ONE, vol. 4, no. 8, Article ID e6690, 2009. View at Publisher · View at Google Scholar · View at Scopus
  181. V. Badot, P. Durez, B. J. van den Eynde, A. Nzeusseu-Toukap, F. A. Houssiau, and B. R. Lauwerys, “Rheumatoid Arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines,” Journal of Cellular and Molecular Medicine, vol. 15, no. 11, pp. 2335–2342, 2011. View at Publisher · View at Google Scholar · View at Scopus
  182. J. Scheller and S. Rose-John, “Interleukin-6 and its receptor: from bench to bedside,” Medical Microbiology and Immunology, vol. 195, no. 4, pp. 173–183, 2006. View at Publisher · View at Google Scholar · View at Scopus
  183. S. Fabre, C. Guisset, L. Tatem et al., “Protein biochip array technology to monitor rituximab in Rheumatoid Arthritis,” Clinical and Experimental Immunology, vol. 155, no. 3, pp. 395–402, 2009. View at Publisher · View at Google Scholar · View at Scopus
  184. M. M. Maurice, H. Nakamura, E. A. M. van der Voort et al., “Evidence for the role of an altered redox state in hyporesponsiveness of synovial T cells in Rheumatoid Arthritis,” Journal of Immunology, vol. 158, no. 3, pp. 1458–1465, 1997. View at Google Scholar · View at Scopus
  185. A. P. Cope, R. S. Liblau, X.-D. Yang et al., “Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling,” Journal of Experimental Medicine, vol. 185, no. 9, pp. 1573–1584, 1997. View at Publisher · View at Google Scholar · View at Scopus
  186. P. H. J. Remans, S. I. Gringhuis, J. M. van Laar et al., “Rap1 signaling is required for suppression of Ras-generated reactive oxygen species and protection against oxidative stress in T lymphocytes,” Journal of Immunology, vol. 173, no. 2, pp. 920–931, 2004. View at Google Scholar · View at Scopus
  187. P. H. J. Remans, C. A. Wijbrandts, M. E. Sanders et al., “CTLA-4Ig suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPase mediator of oxidative stress in Rheumatoid Arthritis T cells,” Arthritis & Rheumatism, vol. 54, no. 10, pp. 3135–3143, 2006. View at Publisher · View at Google Scholar · View at Scopus
  188. J. R. F. Abreu, S. Krausz, W. Dontje et al., “Sustained T cell Rap1 signaling is protective in the collagen-induced arthritis model of Rheumatoid Arthritis,” Arthritis & Rheumatism, vol. 62, no. 11, pp. 3289–3299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  189. F. Ponchel, A. W. Morgan, S. J. Bingham et al., “Dysregulated lymphocyte proliferation and differentiation in patients with Rheumatoid Arthritis,” Blood, vol. 100, no. 13, pp. 4550–4556, 2002. View at Publisher · View at Google Scholar · View at Scopus
  190. D. Unutmaz, P. Pileri, and S. Abrignani, “Antigen-independent activation of naive and memory resting T cells by a cytokine combination,” Journal of Experimental Medicine, vol. 180, no. 3, pp. 1159–1164, 1994. View at Publisher · View at Google Scholar · View at Scopus
  191. D. Unutmaz, F. Baldoni, and S. Abrignani, “Human naive T cells activated by cytokines differentiate into a split phenotype with functional features intermediate between naive and memory T cells,” International Immunology, vol. 7, no. 9, pp. 1417–1424, 1995. View at Google Scholar · View at Scopus
  192. F. M. Brennan, A. L. Hayes, C. J. Ciesielski, P. Green, B. M. Foxwell, and M. Feldmann, “Evidence that Rheumatoid Arthritis synovial T cells are similar to cytokine-activated T cells—involvement of phosphatidylinositol 3-kinase and nuclear factor kappa B pathways in tumor necrosis factor a production in Rheumatoid Arthritis,” Arthritis & Rheumatism, vol. 46, no. 1, pp. 31–41, 2002. View at Google Scholar
  193. J. T. Beech, E. Andreakos, C. J. Ciesielski, P. Green, B. M. J. Foxwell, and F. M. Brennan, “T-cell contact-dependent regulation of CC and CXC chemokine production in monocytes through differential involvement of NFκB: implications for Rheumatoid Arthritis,” Arthritis Research & Therapy, vol. 8, no. 6, article R168, 2006. View at Publisher · View at Google Scholar · View at Scopus
  194. L. Altomonte, A. Zoli, L. Mirone, P. Scolieri, and M. Magaro, “Serum levels of interleukin-1b, tumour necrosis factor-a and interleukin-2 in Rheumatoid Arthritis. Correlation with disease activity,” Clinical Rheumatology, vol. 11, no. 2, pp. 202–205, 1992. View at Publisher · View at Google Scholar · View at Scopus
  195. C. H. Burgoyne, S. L. Field, A. K. Brown et al., “Abnormal T-cell differentiation persists in Rheumatoid Arthritis patients in clinical remission and predicts relapse,” Annals of the Rheumatic Diseases, vol. 67, no. 6, pp. 750–757, 2008. View at Publisher · View at Google Scholar
  196. S. M. Churchman and F. Ponchel, “Interleukin-7 in Rheumatoid Arthritis,” Rheumatology, vol. 47, no. 6, pp. 753–759, 2008. View at Publisher · View at Google Scholar · View at Scopus
  197. S. Harada, M. Yamamura, H. Okamoto et al., “Production of interleukin-7 and interleukin-15 by fibroblast- like synoviocytes from patients with Rheumatoid Arthritis,” Arthritis & Rheumatism, vol. 42, no. 7, pp. 1508–1516, 1999. View at Google Scholar
  198. S. Blaschke, H. Schulz, G. Schwarz, V. Blaschke, G. A. Müller, and M. Reuss-Borst, “Interleukin 16 expression in relation to disease activity in Rheumatoid Arthritis,” Journal of Rheumatology, vol. 28, no. 1, pp. 12–21, 2001. View at Google Scholar · View at Scopus
  199. H. Amital, V. Barak, R. E. Winkler, and A. Rubinow, “Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis,” Annals of the New York Academy of Sciences, vol. 1110, no. 1, pp. 649–660, 2007. View at Publisher · View at Google Scholar · View at Scopus
  200. L. A. B. Joosten, T. R. D. Radstake, E. Lubberts et al., “Association of interleukin-18 expression with enhanced levels of both interleukin-1β and tumor necrosis factor α in knee synovial tissue of patients with Rheumatoid Arthritis,” Arthritis & Rheumatism, vol. 48, no. 2, pp. 339–347, 2003. View at Publisher · View at Google Scholar · View at Scopus
  201. E. A. Gouda, A. A. Aboulata, A. S. Elharoun et al., “Interleukin-18 expression in rheumatoid artheritis synovial tissue and its relation to disease activity,” The Egyptian Journal of Immunology, vol. 14, no. 2, pp. 1–10, 2007. View at Google Scholar · View at Scopus
  202. X. Niu, D. He, X. Zhang et al., “IL-21 regulates Th17 cells in Rheumatoid Arthritis,” Human Immunology, vol. 71, no. 4, pp. 334–341, 2010. View at Publisher · View at Google Scholar · View at Scopus
  203. O. Elkayam, I. Yaron, I. Shirazi, M. Yaron, and D. Caspi, “Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis,” Rheumatology International, vol. 19, no. 3, pp. 101–105, 2000. View at Google Scholar · View at Scopus
  204. S. E. Jacob, M. Nassiri, F. A. Kerdel, and V. Vincek, “Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity,” Mediators of Inflammation, vol. 12, no. 5, pp. 309–313, 2003. View at Publisher · View at Google Scholar · View at Scopus
  205. O. Arican, M. Aral, S. Sasmaz, and P. Ciragil, “Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity,” Mediators of Inflammation, vol. 2005, no. 5, pp. 273–279, 2005. View at Publisher · View at Google Scholar · View at Scopus
  206. E. V. Lourenço and A. la Cava, “Cytokines in systemic lupus erythematosus,” Current Molecular Medicine, vol. 9, no. 3, pp. 242–254, 2009. View at Publisher · View at Google Scholar · View at Scopus
  207. K. N. Lai and D. Y. H. Yap, “Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 365083, 10 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  208. M. Vazquez-del Mercado, A. Garcia-Gonzalez, J. F. Muñoz-Valle et al., “Interleukin 1β (IL-Lβ), IL-10, tumor necrosis factor-α, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis,” Journal of Rheumatology, vol. 29, no. 3, pp. 522–526, 2002. View at Google Scholar · View at Scopus
  209. J. Gratacos, A. Collado, X. Filella et al., “Serum cytokines (IL-6, TNF-α, IL-β and IFN-γ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity,” British Journal of Rheumatology, vol. 33, no. 10, pp. 927–931, 1994. View at Google Scholar · View at Scopus
  210. A. Bal, E. Unlu, G. Bahar, E. Aydog, E. Eksioglu, and R. Yorgancioglu, “Comparison of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis,” Clinical Rheumatology, vol. 26, no. 2, pp. 211–215, 2007. View at Publisher · View at Google Scholar · View at Scopus
  211. B. W. Needleman, F. M. Wigley, and R. W. Stair, “Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma,” Arthritis & Rheumatism, vol. 35, no. 1, pp. 67–72, 1992. View at Google Scholar · View at Scopus
  212. M. Hasegawa and K. Takehara, “Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines,” Seminars in Arthritis and Rheumatism, vol. 42, no. 3, pp. 281–296, 2012. View at Publisher · View at Google Scholar · View at Scopus
  213. A. L. M. A. Jansen, I. E. van der Horst-Bruinsma, D. van Schaardenburg, R. J. van de Stadt, M. H. M. T. de Koning, and B. A. C. Dijkmans, “Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate Rheumatoid Arthritis from undifferentiated polyarthritis in patients with early arthritis,” Journal of Rheumatology, vol. 29, no. 10, pp. 2074–2076, 2002. View at Google Scholar · View at Scopus
  214. V. Goëb, F. Jouen, D. Gilbert, X. le Loët, F. Tron, and O. Vittecoq, “Diagnostic and prognostic usefulness of antibodies to citrullinated peptides,” Joint Bone Spine, vol. 76, no. 4, pp. 343–349, 2009. View at Publisher · View at Google Scholar · View at Scopus
  215. P. E. Barker, “Cancer biomarker validation: standards and process—roles for the National Institute of Standards and Technology (NIST),” Annals of the New York Academy of Sciences, vol. 983, pp. 142–150, 2003. View at Google Scholar · View at Scopus
  216. J. D. Cañete, J. Llena, A. Collado et al., “Comparative cytokine gene expression in synovial tissue of early Rheumatoid Arthritis and seronegative spondyloarthropathies,” British Journal of Rheumatology, vol. 36, no. 1, pp. 38–42, 1997. View at Google Scholar · View at Scopus
  217. M. D. S. Hoy, J. L. Williams, and B. W. Kirkham, “Symmetrical synovial fluid cell cytokine messenger RNA expression in Rheumatoid Arthritis: analysis by reverse transcription/polymerase chain reaction,” British Journal of Rheumatology, vol. 36, no. 2, pp. 170–173, 1997. View at Google Scholar · View at Scopus
  218. K. Raza, F. Falciani, S. J. Curnow et al., “Early Rheumatoid Arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin,” Arthritis Research & Therapy, vol. 7, no. 4, pp. R784–R795, 2005. View at Google Scholar · View at Scopus
  219. H. Kokkonen, I. Söderström, J. Rocklöv, G. Hallmans, K. Lejon, and S. R. Dahlqvist, “Up-regulation of cytokines and chemokines predates the onset of Rheumatoid Arthritis,” Arthritis & Rheumatism, vol. 62, no. 2, pp. 383–391, 2010. View at Publisher · View at Google Scholar · View at Scopus
  220. K. T. Jørgensen, A. Wiik, M. Pedersen et al., “Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with Rheumatoid Arthritis: case-control study nested in a cohort of Norwegian blood donors,” Annals of the Rheumatic Diseases, vol. 67, no. 6, pp. 860–866, 2008. View at Publisher · View at Google Scholar · View at Scopus
  221. T. J. Fry and C. L. Mackall, “Interleukin-7: master regulator of peripheral T-cell homeostasis?” Trends in Immunology, vol. 22, no. 10, pp. 564–571, 2001. View at Publisher · View at Google Scholar · View at Scopus
  222. F. Ponchel, R. J. Cuthbert, and V. Goëb, “IL-7 and lymphopenia,” Clinica Chimica Acta, vol. 412, no. 1-2, pp. 7–16, 2011. View at Publisher · View at Google Scholar · View at Scopus
  223. M. Natsumeda, K. Nishiya, and Z. Ota, “Stimulation by interleukin-7 of mononuclear cells in peripheral blood, synovial fluid and synovial tissue from patients with Rheumatoid Arthritis,” Acta Medica Okayama, vol. 47, no. 6, pp. 391–397, 1993. View at Google Scholar · View at Scopus
  224. J. A. G. van Roon, M. C. Verweij, M. W.-V. Wijk, K. M. G. Jacobs, J. W. J. Bijlsma, and F. P. J. G. Lafeber, “Increased intraarticular interleukin-7 in Rheumatoid Arthritis patients stimulates cell contact-depedent activation of CD4+ T cells and macrophages,” Arthritis & Rheumatism, vol. 52, no. 6, pp. 1700–1710, 2005. View at Publisher · View at Google Scholar · View at Scopus
  225. T. Makino, S. Fukushima, S. Wakasugi, and H. Ihn, “Decreased serum IL-7 levels in patients with systemic sclerosis,” Clinical and Experimental Rheumatology, vol. 27, no. 3, pp. S68–S69, 2009. View at Google Scholar · View at Scopus
  226. J. C. Andreu-Ballester, J. Pérez-Griera, C. Garcia-Ballesteros et al., “Deficit of interleukin-7 in serum of patients with Crohn's disease,” Inflammatory Bowel Diseases, vol. 19, no. 2, pp. E30–E31, 2013. View at Publisher · View at Google Scholar · View at Scopus
  227. H. A. Kader, V. T. Tchernev, E. Satyaraj et al., “Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-β1 and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease,” The American Journal of Gastroenterology, vol. 100, no. 2, pp. 414–423, 2005. View at Publisher · View at Google Scholar · View at Scopus
  228. H. L. Wright, R. C. Bucknall, R. J. Moots, and S. W. Edwards, “Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy,” Rheumatology, vol. 51, no. 3, Article ID ker338, pp. 451–459, 2012. View at Publisher · View at Google Scholar · View at Scopus
  229. S. Das, E. M. Vital, S. Horton et al., “Abatacept or tocilizumab after rituximab in Rheumatoid Arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy,” Annals of the Rheumatic Diseases, 2014. View at Publisher · View at Google Scholar
  230. C. A. Wijbrandts, M. G. W. Dijkgraaf, M. C. Kraan et al., “The clinical response to infliximab in Rheumatoid Arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium,” Annals of the Rheumatic Diseases, vol. 67, no. 8, pp. 1139–1144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  231. J. Lindberg, E. af Klint, A. I. Catrina et al., “Effect of infliximab on mRNA expression profiles in synovial tissue of Rheumatoid Arthritis patients,” Arthritis Research & Therapy, vol. 8, article R179, 2006. View at Publisher · View at Google Scholar · View at Scopus
  232. T. C. M. van der Pouw Kraan, C. A. Wijbrandts, L. G. van Baarsen et al., “Responsiveness to anti-tumour necrosis factor α therapy is related to pre-treatment tissue inflammation levels in Rheumatoid Arthritis patients,” Annals of the Rheumatic Diseases, vol. 67, no. 4, pp. 563–566, 2008. View at Publisher · View at Google Scholar · View at Scopus
  233. H. Marotte, W. Maslinski, and P. Miossec, “Circulating tumour necrosis factor-alpha bioactivity in Rheumatoid Arthritis patients treated with infliximab: link to clinical response,” Arthritis Research & Therapy, vol. 7, no. 1, pp. R149–R155, 2005. View at Google Scholar · View at Scopus
  234. D. Koczan, S. Drynda, M. Hecker et al., “Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in Rheumatoid Arthritis by etanercept,” Arthritis Research & Therapy, vol. 10, no. 3, article R50, 2008. View at Publisher · View at Google Scholar · View at Scopus
  235. T. Häupl, B. Stuhlmüller, A. Grützkau, A. Radbruch, and G.-R. Burmester, “Does gene expression analysis inform us in Rheumatoid Arthritis?” Annals of the Rheumatic Diseases, vol. 69, supplement 1, pp. i37–i42, 2010. View at Publisher · View at Google Scholar · View at Scopus
  236. B. Stuhlmüller, T. Häupl, N. Tandon et al., “Microarray analysis for molecular characterization of disease activity and measuring outcomes of anti-tumour necrosis factor therapy in Rheumatoid Arthritis,” Arthritis Research & Therapy, vol. 7, article P159, 2005. View at Publisher · View at Google Scholar
  237. T. Lequerré, A.-C. Gauthier-Jauneau, C. Bansard et al., “Gene profiling in white blood cells predicts infliximab responsiveness in Rheumatoid Arthritis,” Arthritis Research & Therapy, vol. 8, no. 4, article R105, 2006. View at Publisher · View at Google Scholar
  238. A. Julià, A. Erra, C. Palacio et al., “An eight-gene blood expression profile predicts the response to infliximab in Rheumatoid Arthritis,” PLoS ONE, vol. 4, no. 10, Article ID e7556, 2009. View at Publisher · View at Google Scholar · View at Scopus
  239. S. M. Zivojinovic, N. N. Pejnovic, M. N. Sefik-Bukilica, L. V. Kovacevic, I. I. Soldatovic, and N. S. Damjanov, “Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in Rheumatoid Arthritis,” Journal of Rheumatology, vol. 39, no. 1, pp. 18–21, 2012. View at Publisher · View at Google Scholar · View at Scopus
  240. R. M. Thurlings, M. Boumans, J. Tekstra et al., “Relationship between the type I interferon signature and the response to rituximab in Rheumatoid Arthritis patients,” Arthritis & Rheumatism, vol. 62, no. 12, pp. 3607–3614, 2010. View at Publisher · View at Google Scholar · View at Scopus
  241. S. Vosslamber, H. G. Raterman, T. C. T. M. van der Pouw Kraan et al., “Pharmacological induction of interferon type i activity following treatment with rituximab determines clinical response in Rheumatoid Arthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 6, pp. 1153–1159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  242. L. G. M. van Baarsen, C. A. Wijbrandts, F. Rustenburg et al., “Regulation of IFN response gene activity during infliximab treatment in Rheumatoid Arthritis is associated with clinical response to treatment,” Arthritis Research & Therapy, vol. 12, no. 1, article R11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  243. J. Lübbers, M. Brink, L. A. van de Stadt et al., “The type I IFN signature as a biomarker of preclinical Rheumatoid Arthritis,” Annals of the Rheumatic Diseases, vol. 72, no. 5, pp. 776–780, 2013. View at Publisher · View at Google Scholar
  244. G. Tesch, S. Amur, J. T. Schousboe, J. N. Siegel, L. J. Lesko, and J. P. F. Bai, “Successes achieved and challenges ahead in translating biomarkers into clinical applications,” The AAPS Journal, vol. 12, no. 3, pp. 243–253, 2010. View at Publisher · View at Google Scholar · View at Scopus
  245. M. Pirmohamed, “Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles,” Clinical Pharmacology and Therapeutics, vol. 88, no. 6, pp. 862–866, 2010. View at Publisher · View at Google Scholar · View at Scopus